At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing ...

Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing ...

PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around ...

Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains. The rise in cell ...

Gross-to-net concessions exceeding half of U.S. brand revenue make minor contracting and payment inefficiencies translate into hundreds of millions in leakage or compliance risk. Legacy revenue ...

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain ...

Raquel Vazquez discusses how data can be incorporated to make key decisions within the cold chain.

In this week’s Pharma Pulse, GEODIS’ cold chain expansion in the Midwest, a potential multi-billion dollar shift in cell therapy, and the White House’s new push for psychedelic mental health ...

EPS for ~3-day lanes, polyurethane for higher performance, and vacuum insulation panels for maximum duration—still anchor ...

Risk concentrates at transfer points and the final mile, where multiple touchpoints, tight delivery windows, and site-specific requirements can rapidly convert routine moves into service failures.

Pharmaceutical cold chain logistics is entering a phase where data quality and decision speed matter as much as physical ...